DrugPatentWatch Database Preview
IRINOTECAN HYDROCHLORIDE Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Irinotecan Hydrochloride, and what generic alternatives are available?
Irinotecan Hydrochloride is a drug marketed by Accord Hlthcare, Actavis Totowa, Akorn, Cipla Ltd, Emcure Pharms Ltd, Fresenius Kabi Oncol, Fresenius Kabi Usa, Hikma Farmaceutica, Hisun Pharm Hangzhou, Hospira, Ingenus Pharms Llc, Intas Pharms Usa, Jiangsu Hengrui Med, Mustafa Nevzat Ilac, Neopharma, Pliva Lachema, Qilu Pharm Co Ltd, Sandoz, Sandoz Inc, Sun Pharma Global, Teva Pharms Usa, and West-ward Pharms Int. and is included in twenty-three NDAs.
The generic ingredient in IRINOTECAN HYDROCHLORIDE is irinotecan hydrochloride. There are thirty-three drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.
Summary for IRINOTECAN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 22 |
| NDAs: | 23 |
| Suppliers / Packagers: | 14 |
| Bulk Api Vendors: | 65 |
| Clinical Trials: | 1,081 |
| Patent Applications: | 3,771 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | IRINOTECAN HYDROCHLORIDE at DailyMed |
Pharmacology for IRINOTECAN HYDROCHLORIDE
| Drug Class | Topoisomerase Inhibitor |
| Mechanism of Action | Topoisomerase Inhibitors |
Synonyms for IRINOTECAN HYDROCHLORIDE
| (1,4'-Bipiperidine)-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, monohydrochloride |
| (1,4'-Bipiperidine)-1'-carboxylic acid, 3,4,12,14-tetrahydro-4,11-diethyl-4-hydroxy-3,4-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, monohydrochloride, (S)- |
| (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride |
| (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0?,??.0?,?.0??,??]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate hydrochloride |
| (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0(2),(1)(1).0,.0(1),(2)]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate hydrochloride |
| (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylic acid ester hydrochloride |
| (4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]chinolin-9-yl-1,4'-bipiperidin-1'-carboxylathydrochlorid |
| (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride |
| (S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride |
| (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3 inverted exclamation marka,4 inverted exclamation marka:6,7]indolizino[1,2-b]quinolin-9-yl ester |
| (S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3 inverted exclamation marka,4 inverted exclamation marka:6,7]indolizino[1,2-b]quinolin-9-yl ester; [1,4 inverted exclamation marka-Bipiperidine]-1 inverted |
| (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride |
| [1, 4,11-diethyl-3,4,12, 14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7] indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride (S)- |
| [1,4 inverted exclamation mark -Bipiperidine]-1 inverted exclamation mark -carboxylic Acid (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]in |
| [1,4 inverted exclamation marka-Bipiperidine]-1 inverted exclamation marka-carboxylic acid |
| 06X131E4OE |
| 1-[1-({[(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]oxy}carbonyl)piperidin-4-yl]piperidin-1-ium chloride |
| 100286-90-6 |
| 111348-33-5 |
| 286I906 |
| 7-Ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy camptothecin hydrochloride |
| AB0013307 |
| AB1004843 |
| AC-28335 |
| AC1L2MZI |
| AC1Q3ESY |
| AK163168 |
| AKOS015901921 |
| AN-34403 |
| AS-13304 |
| BC206170 |
| C33H38N4O6.HCl |
| Campto |
| Camptosar (TN) (Pharmacia) |
| Camptothecin 11 |
| Camptothecin 11 hydrochloride |
| Camptothecin analog |
| CAS-100286-90-6 |
| CCG-213561 |
| CHEBI:5971 |
| CHEMBL541887 |
| CPT 11 |
| CPT-11 |
| CPT11, |
| CS-2988 |
| DQ-2805 |
| DSSTox_CID_25953 |
| DSSTox_GSID_45953 |
| DSSTox_RID_81249 |
| DTXSID6045953 |
| EBD19661 |
| FT-0627291 |
| GURKHSYORGJETM-WAQYZQTGSA-N |
| H851 |
| HMS1922J04 |
| HY-16562A |
| I0714 |
| Irinotecan (hydrochloride) |
| Irinotecan Hcl |
| irinotecan hydrochloride (anhydrous) |
| Irinotecan hydrochloride [USAN:JAN] |
| Irinotecan hydrochloride, topoisomerase inhibitor |
| irinotecan monohydrochloride |
| KS-00000Y33 |
| LS-44591 |
| MCULE-3850427409 |
| MFCD01862255 |
| MolPort-003-666-755 |
| NCGC00095190-01 |
| NCGC00095190-02 |
| NCGC00178697-04 |
| NE46825 |
| NSC-616348 |
| NSC-759878 |
| NSC616348 |
| NSC759878 |
| Pharmakon1600-01505821 |
| Q-100016 |
| RL00025 |
| SCHEMBL4033 |
| SPECTRUM1505821 |
| ST24047422 |
| ST51054057 |
| TL8000040 |
| Topotecin |
| Tox21_111479 |
| Tox21_111479_1 |
| U 101440E |
| U-101440E |
| UNII-06X131E4OE |
| Z1550648758 |
US Patents and Regulatory Information for IRINOTECAN HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | IRINOTECAN HYDROCHLORIDE | irinotecan hydrochloride | INJECTABLE;INJECTION | 090137-002 | Nov 12, 2009 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Neopharma | IRINOTECAN HYDROCHLORIDE | irinotecan hydrochloride | INJECTABLE;INJECTION | 078953-002 | Apr 15, 2010 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Teva Pharms Usa | IRINOTECAN HYDROCHLORIDE | irinotecan hydrochloride | INJECTABLE;INJECTION | 090101-003 | Feb 27, 2008 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Jiangsu Hengrui Med | IRINOTECAN HYDROCHLORIDE | irinotecan hydrochloride | INJECTABLE;INJECTION | 090675-001 | Dec 16, 2011 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
